At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 172 enrolled
Drug / intervention
Bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab for Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis. Completed, enrolled 172 participants across 39 sites in 2 countries.
Detailed Summary
The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection technique using a prefilled safety syringe or an auto-injector.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartDec 2018
Primary CompletionJul 2020
Study CompletionSep 2020
TodayJul 2026
First PostedDec 6, 2018
Enrollment StartDec 20, 2018
Primary CompletionJul 14, 2020
Study CompletionSep 8, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.6 years ago
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at pre-specified time-points.